| scholarly article | Q13442814 |
| P50 | author | Jules Dienstag | Q69897087 |
| Adrian M. Di Bisceglie | Q87445433 | ||
| P2093 | author name string | Leonard B Seeff | |
| Herbert L Bonkovsky | |||
| Gyongyi Szabo | |||
| Gregory T Everson | |||
| William M Lee | |||
| Karen L Lindsay | |||
| Anna S F Lok | |||
| Marc G Ghany | |||
| Mitchell L Shiffman | |||
| HALT-C Trial Group | |||
| Teresa M Curto | |||
| P2860 | cites work | Factors associated with herbal use among urban multiethnic primary care patients: a cross-sectional survey | Q24809755 |
| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 | ||
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Chemotherapy of Amanita phalloides poisoning with intravenous silibinin | Q28275080 | ||
| Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey | Q29547851 | ||
| Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose | Q29547886 | ||
| Histological grading and staging of chronic hepatitis | Q29619625 | ||
| Diagnosis, management, and treatment of hepatitis C | Q29620656 | ||
| The use of silymarin in the treatment of liver diseases | Q34104302 | ||
| Antioxidant properties of silybin glycosides | Q34122120 | ||
| Use of complementary and alternative medicine in patients with liver disease | Q34152596 | ||
| Herbs and alternative therapies in the hypertension clinic | Q34391962 | ||
| Milk thistle for alcoholic and/or hepatitis B or C liver diseases--a systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials | Q34466391 | ||
| The use of selected nutrition supplements and complementary and alternative medicine in liver disease | Q34554574 | ||
| Complementary and alternative medicine in hepatology: review of the evidence of efficacy | Q34601751 | ||
| Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin | Q34626058 | ||
| Milk thistle for the treatment of liver disease: a systematic review and meta-analysis | Q34994556 | ||
| Use of herbal supplements for chronic liver disease | Q35954419 | ||
| Herbal medicines for liver diseases | Q36269281 | ||
| Silymarin treatment of viral hepatitis: a systematic review | Q36300100 | ||
| Silybin and silymarin--new and emerging applications in medicine | Q36737890 | ||
| Herbal medicine in the treatment of liver diseases | Q36748782 | ||
| Silymarin, an inhibitor of lipoxygenase | Q39704397 | ||
| Long-term trends in the use of complementary and alternative medical therapies in the United States | Q40690921 | ||
| Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells | Q40696498 | ||
| Two-year results of a randomised double-blinded trial evaluating silymarin for chronic hepatitis C. | Q42993395 | ||
| Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C. | Q42998101 | ||
| Herbal therapy for management of obesity: observations from a clinical endocrinology practice | Q43826091 | ||
| Silymarin increases antioxidant enzymes in alloxan-induced diabetes in rat pancreas | Q44682480 | ||
| Herbal and vitamin supplement use in a prostate cancer screening population | Q44769694 | ||
| Prevalence and predictors of herbal medication use in veterans with chronic hepatitis C. | Q44962463 | ||
| Use of herbal/natural supplements according to racial/ethnic group. | Q46834552 | ||
| Herb and supplement use in the US adult population. | Q46861534 | ||
| The use of herbal supplements and alternative therapies by patients with amyotrophic lateral sclerosis (ALS). | Q46977869 | ||
| Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. | Q50580484 | ||
| Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. | Q50892403 | ||
| National Patterns and Correlates of Complementary and Alternative Medicine Use in Adults with Diabetes | Q56049516 | ||
| Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver | Q56224573 | ||
| Utilization of complementary and alternative medicine by United States adults: results from the 1999 national health interview survey | Q64128161 | ||
| Hepatitis induced by Kava (Piper methysticum rhizoma) | Q73561725 | ||
| Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase | Q73714775 | ||
| Herbal hepatotoxicity | Q80853381 | ||
| Medicinal herb use in a population-based survey of adults: prevalence and frequency of use, reasons for use, and use among their children | Q81202142 | ||
| Herbal hepatotoxicity | Q81235309 | ||
| An in vitro study of the protective effect of the flavonoid silydianin against reactive oxygen species | Q82414349 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | liver cirrhosis | Q147778 |
| hepatitis C | Q154869 | ||
| P304 | page(s) | 605-612 | |
| P577 | publication date | 2008-02-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial | |
| P478 | volume | 47 |
| Q37323461 | A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis |
| Q37422735 | A systematic approach to evaluate herb-drug interaction mechanisms: investigation of milk thistle extracts and eight isolated constituents as CYP3A inhibitors. |
| Q83578903 | Advanced chronic hepatitis C: how to handle if you cannot halt? |
| Q33894202 | Antioxidant and immunomodulatory effects of Viusid in patients with chronic hepatitis C. |
| Q81353317 | Antiviral effects of silymarin against hepatitis C: the jury is still out |
| Q35958261 | Beneficial effects of fucoidan in patients with chronic hepatitis C virus infection. |
| Q36353469 | Cell culture-derived HCV cannot infect synovial fibroblasts |
| Q38550165 | Chemoprevention against hepatocellular carcinoma |
| Q48046773 | Complementary and Alternative Medicine Use in United States Adults With Liver Disease |
| Q34411345 | Complementary and alternative medications in hepatitis C infection. |
| Q37061693 | Complementary and alternative medicine use in chronic liver disease patients |
| Q92703615 | Complex Evaluation of Antioxidant Capacity of Milk Thistle Dietary Supplements |
| Q36454762 | Critical review of resveratrol in xenobiotic-induced hepatotoxicity. |
| Q26775055 | Current Status of Herbal Medicines in Chronic Liver Disease Therapy: The Biological Effects, Molecular Targets and Future Prospects |
| Q29619682 | Diagnosis, management, and treatment of hepatitis C: an update |
| Q30997889 | Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation |
| Q26864887 | Drug-drug interactions during antiviral therapy for chronic hepatitis C |
| Q38084215 | Drug-induced liver injury: the role of drug metabolism and transport |
| Q36933129 | Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial |
| Q41729153 | Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: a meta-analysis of randomized controlled trials. |
| Q35405665 | Effects of 18α-glycyrrhizin on TGF-β1/Smad signaling pathway in rats with carbon tetrachloride-induced liver fibrosis |
| Q39951846 | Effects of silymarin on hepatitis C virus and haem oxygenase-1 gene expression in human hepatoma cells |
| Q36637707 | Efficacy and safety of Chlorella supplementation in adults with chronic hepatitis C virus infection |
| Q36142772 | Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection |
| Q37139671 | Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2). |
| Q42994110 | Hepatitis C virus induces oxidative stress, DNA damage and modulates the DNA repair enzyme NEIL1. |
| Q83992415 | Hepatitis C: new therapeutic strategies needed for advanced disease |
| Q36675737 | Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection |
| Q37603890 | Herb-drug interactions: challenges and opportunities for improved predictions. |
| Q93140956 | Herbal and dietary supplement hepatotoxicity |
| Q93016049 | Herbal drug discovery for the treatment of nonalcoholic fatty liver disease |
| Q21284956 | Herbal products: benefits, limits, and applications in chronic liver disease |
| Q36807240 | HiFSA fingerprinting applied to isomers with near-identical NMR spectra: the silybin/isosilybin case |
| Q24600492 | Identification of hepatoprotective flavonolignans from silymarin |
| Q36776621 | Interaction of silymarin flavonolignans with organic anion-transporting polypeptides |
| Q51507299 | Investigating the potential for toxicity from long-term use of the herbal products, goldenseal and milk thistle. |
| Q39560356 | Legalon-SIL downregulates HCV core and NS5A in human hepatocytes expressing full-length HCV. |
| Q37801596 | Management of Untreated and Nonresponder Patients with Chronic Hepatitis C |
| Q57729906 | Micronised purified flavonoid fraction alleviates the carbon tetrachloride-induced hepatic injury |
| Q38058825 | Milk thistle and its derivative compounds: a review of opportunities for treatment of liver disease |
| Q39698364 | Multiple effects of silymarin on the hepatitis C virus lifecycle |
| Q50934392 | Natural History of Hepatitis C. |
| Q26775036 | Natural Products as Tools for Defining How Cellular Metabolism Influences Cellular Immune and Inflammatory Function during Chronic Infection |
| Q41918847 | Null anticarcinogenic effect of silymarin on diethylnitrosamine-induced hepatocarcinogenesis in rats |
| Q36417913 | Nutrition therapy for liver diseases based on the status of nutritional intake |
| Q50077257 | Phytotherapeutics: The Emerging Role of Intestinal and Hepatocellular Transporters in Drug Interactions with Botanical Supplements |
| Q26801951 | Plants Consumption and Liver Health |
| Q33694159 | Processes to manage analyses and publications in a phase III multicenter randomized clinical trial |
| Q38264060 | Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection: Joint Opinion of the GI/Liver/Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy |
| Q34342554 | Review article: prescribing medications in patients with cirrhosis - a practical guide |
| Q47589231 | Role of MAIT cells in the immunopathogenesis of inflammatory diseases: New players in old game. |
| Q50947917 | Role of UDP-Glucuronosyltransferase 1A1 in the Metabolism and Pharmacokinetics of Silymarin Flavonolignans in Patients with HCV and NAFLD. |
| Q35222402 | Safety and efficacy of Qurse-e-istisqua in chronic hepatitis C infection: an exploratory study |
| Q38332651 | Severe Cholestasis and Bile Acid Nephropathy From Anabolic Steroids Successfully Treated With Plasmapheresis |
| Q48231856 | Silibinin affects the pharmacokinetics of methadone in rats |
| Q34359120 | Silibinin inhibits HIV-1 infection by reducing cellular activation and proliferation |
| Q34629765 | Silybin and the liver: from basic research to clinical practice. |
| Q36192046 | Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability. |
| Q34914880 | Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C |
| Q26851453 | Silymarin for HCV infection |
| Q27490911 | Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection |
| Q36269639 | Silymarin suppresses basal and stimulus-induced activation, exhaustion, differentiation, and inflammatory markers in primary human immune cells |
| Q36374902 | Silymarin use and liver disease progression in the Hepatitis C Antiviral Long‐Term Treatment against Cirrhosis trial |
| Q37824811 | Targeting cell entry of enveloped viruses as an antiviral strategy. |
| Q35894929 | Understanding silibinin's modes of action against HCV using viral kinetic modeling |
| Q42988125 | Viral hepatitis: Drug-drug interactions in HCV treatment--the good, the bad and the ugly |
Search more.